Filing Details

Accession Number:
0001209191-16-113717
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-04-08 14:30:27
Reporting Period:
2016-04-06
Filing Date:
2016-04-08
Accepted Time:
2016-04-08 14:30:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1175505 Five Prime Therapeutics Inc FPRX Pharmaceutical Preparations (2834) 260038620
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1382629 Marc Belsky Two Corporate Drive
South San Francisco CA 94080
Senior Vice President And Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-04-06 351 $4.56 81,278 No 4 M Direct
Common Stock Acquisiton 2016-04-06 11,382 $6.89 92,660 No 4 M Direct
Common Stock Acquisiton 2016-04-06 8,943 $8.49 101,603 No 4 M Direct
Common Stock Acquisiton 2016-04-06 138 $5.54 101,741 No 4 M Direct
Common Stock Disposition 2016-04-06 20,814 $45.04 80,927 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2016-04-06 351 $0.00 351 $4.56
Common Stock Employee Stock Option (right to buy) Disposition 2016-04-06 11,382 $0.00 11,382 $6.89
Common Stock Employee Stock Option (right to buy) Disposition 2016-04-06 8,943 $0.00 8,943 $8.49
Common Stock Employee Stock Option (right to buy) Disposition 2016-04-06 138 $0.00 138 $5.54
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2019-10-20 No 4 M Direct
0 2020-07-28 No 4 M Direct
0 2021-07-13 No 4 M Direct
7,992 2022-07-15 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on November 30, 2015.
  2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from 45.00 to $45.16, inclusive. The reporting person undertakes to provide to Five Prime Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4.
  3. This option is fully vested and immediately exercisable.
  4. This option began vesting on July 12, 2012 at a rate of 1/48th per month.